JDM Re: Lefitolimod in metastatic colorectal cancer
Notice where Mologen has terminated negotiations with Oncologie for the global assignment of lefitolimod following deal terms that were inferior to those originally agreed.
Mologen is developing novel immunotherapies for use in the post-chemo maintenance setting (in cancer) and for the treatment of infectious diseases. A pivotal 540-pt Phase III study (IMPALA) for its lead asset lefitolimod in metastatic colorectal cancer maintenance will read out in H219. Mologen has terminated negotiations with Oncologie for the global assignment of lefitolimod following deal terms that were inferior to those originally agreed. Mologen will now look to out-license lefitolimod after the IMPALA trial to achieve the best possible terms. An agreement with the bond holders for its 2016/2024 and 2017/2025 bonds have been reached. The EGM originally scheduled for the 26 February 2019 has been postponed. We note, Mologen has announced the early departure of its CEO Dr Ignacio Faus with effect from 31st March 2019.
Give me pause to question the original agreed upon consent or intent. Or perhaps intent to make null for reason unknown. (?)
News 
Market Data 
Discover 
